Introduction
============

Hepatocellular carcinoma (HCC), one of the leading malignancies, is a major cause of cancer-related death worldwide.[@b1-ott-11-5789] As is known to all, HCC is a consequential complication of cirrhosis.[@b2-ott-11-5789] In addition, epidemiological studies have provided overwhelming evidence that hepatitis B virus (HBV) infection is the main risk factor associated with the occurrence of chronic hepatitis B (CHB), cirrhosis, and HCC. Globally, 257 million people are chronic HBV carriers, and nearly one-quarter of them will develop HCC.[@b3-ott-11-5789]--[@b5-ott-11-5789] Therefore, the progression of HCC in persons persistently infected with HBV is of great significance. However, the mechanisms contributing to the HBV-related HCC have not been fully elucidated.

DNA methylation, a common epigenetic alteration, plays an important role in the regulation of gene expressions and other life activities. Previous studies have shown that aberrant promoter hypermethylation of many tumor suppressor genes (TSGs), which will lead to transcriptional repression and loss of gene function, may play a major role in the progression of tumorigenesis.[@b6-ott-11-5789]--[@b8-ott-11-5789] In recent years, several aberrant methylations of tumor-associated genes have been observed in HCC.[@b9-ott-11-5789]--[@b11-ott-11-5789] In consideration of the significance of HBV in the occurrence of HCC, it is necessary to further study whether aberrant DNA methylation of specific genes exerts a potential role in early detection of HBV-related HCC.

The glutathione S-transferase pi 1 (*GSTP1*) gene is considered to be a major TSG located on chromosome 16p13, belonging to a family of phase II metabolic enzymes, and plays a critical role in the prevention of hepatocyte mutation.[@b12-ott-11-5789] In addition, the *p16^INK4A^* gene is a cell cycle-related gene located on chromosome 9p21 and plays a key role in cell cycle regulation.[@b13-ott-11-5789],[@b14-ott-11-5789] Preliminary reports have reported that GSTP1 and P16 promoter hypermethylation leads to the downregulation of gene expressions and contributes to an increase in the incidence of HBV-related HCC.[@b15-ott-11-5789] However, the relationship of GSTP1 and P16 promoter methylation with HBV-related HCC risk and pathogenesis remains controversial.[@b15-ott-11-5789]--[@b26-ott-11-5789] Therefore, we carried out the current meta-analysis to comprehensively assess the associations of GSTP1 and P16 promoter methylation with the risk of HBV-related HCC.

Methods
=======

Search strategy
---------------

Relevant literature was retrieved from PubMed, Embase, Web of Science, and China National Knowledge Infrastructure databases with a combination of the following words: "Hepatitis B Virus" or "HBV" and "hepatocellular carcinoma" or "HCC" and "GSTP1" or "glutathione-S-transferase P1" or "P16" and "methylation". All relevant articles were published before December 2017, without language restrictions. Literature searches were conducted independently by two reviewers using a standardized approach (Qin Li and Cunliang Deng). The references from relevant primary articles were manually searched to identify potential studies. Any disagreement was adjudicated by a third investigator (Xiang Li) after referring to original articles.

### Inclusion criteria and exclusion criteria

We used the following inclusion criteria for our research: 1) studies that have a case-control design; 2) studies in which patients diagnosed with HBV-related HCC, cirrhosis, and CHB were accurately diagnosed according to the diagnostic criteria; 3) studies in which patients with HBV infection were diagnosed using a HBV surface antigen (HBsAg) serological assay; 4) methods suitable for the methylation detection were confined to MethyLight array, pyrosequencing, and methylation-specific polymerase chain reaction (MSP); and 5) studies primarily evaluating the frequency of GSTP1 or P16 promoter methylation in HBV-related HCC tissues with control group. Studies were excluded if they met one of the following criteria: 1) overlapping data or review articles; 2) studies in which patients had other severe diseases, such as other malignancies, heart failure, or kidney failure; and 3) studies in which patients received a combination of other treatments.

Data extraction
---------------

We recorded the following information: first author, publication year, geographical location, ethnicity, detection method of methylation, and frequency of methylation. The case numbers of HBV-related HCC, cirrhosis, CHB, paracancerous tissue, and normal liver tissue were separately extracted from the overall population after fully understanding the paper.

Statistical analysis
--------------------

Meta-analyses were performed using STATA 12.0 (Stata Corporation, College Station, TX, USA). The strength of the associations between GSTP1 and P16 promoter methylation and the risk of HBV-related HCC was expressed as the ORs and 95% CIs. The *Z*-test was applied to estimate the statistical significance of pooled ORs. Between-study heterogeneity was evaluated by the Cochrane *Q*-statistic and *I*^2^ test. The random-effects model was chosen when heterogeneity existed among studies (*I*^2^\>50%). Otherwise, a fixed-effects model was applied. Sensitivity analysis was carried out to investigate the influence of single study on the final results. Egger's test, Begg's test, and funnel plots were performed to examine the publication bias. The results were displayed as forest plots and identified to be statistically significant when *P*\<0.05.

Results
=======

Characteristics of studies
--------------------------

The process of literature search is summarized in [Figure 1](#f1-ott-11-5789){ref-type="fig"}. The original search yielded a total of 111 articles related to the searched keywords. According to the inclusion criteria, a total of 429 HCC samples with HBV infection in 12 studies were included; additionally, 173 adjacent samples, 167 normal samples, 241 cirrhosis samples, and 190 CHB samples were included. The publication year of the studies ranged from 2003 to 2017.

The geographic setting of the studies was heterogeneous: two studies were from Korea, eight were from China, one was from Japan, and one each from France and Thailand. The MSP method used for this meta-analysis was adopted in eight studies, one study was detected by pyrosequencing, and the other three studies were conducted using MethyLight array. The characteristics of the studies are summarized in [Table 1](#t1-ott-11-5789){ref-type="table"}.

Association of GSTP1 promoter region methylation with the risk of HBV-related HCC
---------------------------------------------------------------------------------

Six studies were included to assess the potential role of GSTP1 promoter methylation in the risk of HCC in patients with HBV infection. A random-effects model was used where significant heterogeneity was found among the studies. Our findings demonstrated that the frequency of the GSTP1 gene methylation in neoplasm tissues was significantly higher than in the normal and cirrhosis tissues (neoplasm tissue vs normal tissue: OR =6.05, 95% CI =1.20--30.52, *P*\<0.05, [Figure 2A](#f2-ott-11-5789){ref-type="fig"} and [Table 2](#t2-ott-11-5789){ref-type="table"}; neoplasm tissue vs cirrhosis tissue: OR =5.21, 95% CI =2.19--12.41, *P*\<0.01, [Figure 2B](#f2-ott-11-5789){ref-type="fig"} and [Table 2](#t2-ott-11-5789){ref-type="table"}).

Association of P16 promoter region methylation with the risk of HBV-related HCC
-------------------------------------------------------------------------------

The pooled OR of P16 methylation in HBV-related HCC tissues was 7.18, with corresponding 95% CI = 2.31--22.33, compared with adjacent tissues in the random-effects model (*P*\<0.01; [Figure 3A](#f3-ott-11-5789){ref-type="fig"} and [Table 2](#t2-ott-11-5789){ref-type="table"}). Compared with normal tissues, the fixed-effects model was chosen to evaluate the association between the frequency of P16 methylation and the risk of HBV-related HCC, and a significant result was found (OR =24.89, 95% CI=3.38--183.03, *P*\<0.01; [Figure 3B](#f3-ott-11-5789){ref-type="fig"} and [Table 2](#t2-ott-11-5789){ref-type="table"}). Moreover, the pooled OR was 5.92 in HBV-related HCC tumor tissues vs cirrhosis tissues (95% CI =1.78--19.68, *P*\<0.01; [Figure 3C](#f3-ott-11-5789){ref-type="fig"} and [Table 2](#t2-ott-11-5789){ref-type="table"}), indicating that P16 methylation in promoter region could obviously increase the risk of HBV-related HCC in patients with cirrhosis. However, no significant association was found between HBV-related HCC tumor tissues and CHB tissues (OR =12.12, 95% CI =0.75--196.50, *P*\>0.05; [Figure 3D](#f3-ott-11-5789){ref-type="fig"} and [Table 2](#t2-ott-11-5789){ref-type="table"}).

Sensitivity analysis
--------------------

Sensitivity analysis was performed to evaluate the effect of each study on overall meta-analysis by excluding one study at a time, but the pooled ORs were always constant, indicating that no individual study significantly affected the overall pooled estimates, and our results were robust.

Publication bias
----------------

Begg's and Egger's tests were used to investigate the publication bias. Begg's funnel plot showed no publication bias for the association between the methylation of GSTP1 and the risk of HBV-related HCC in cancerous and normal tissue, while the Egger's test indicated an opposite result. Moreover, results from our meta-analysis showed that there was no publication bias when assessing the GSTP1 methylation in HBV-related HCC tumor tissues vs cirrhosis tissues ([Table 2](#t2-ott-11-5789){ref-type="table"} and [Figure 4](#f4-ott-11-5789){ref-type="fig"}).

With regard to the association between the methylation of P16 and the risk of HBV-related HCC, the funnel plots presented no apparent asymmetry, and the Egger's tests showed no publication bias in HBV-related HCC tumor tissues vs adjacent tissues, normal tissues, cirrhosis tissues, and CHB tissues ([Table 2](#t2-ott-11-5789){ref-type="table"} and [Figure 5](#f5-ott-11-5789){ref-type="fig"}).

Discussion
==========

To the best of our knowledge, HBV infection is one of the most associated factors in hepatocarcinogenesis. HBV has been proved to integrate into the host genome and interfere with cell proliferation and invasion, DNA repair, as well as epigenetic modification.[@b27-ott-11-5789] In areas with high prevalence of HBV infection, a spectrum of liver disease has been formed, extending from CHB to cirrhosis, even to HCC.[@b28-ott-11-5789],[@b29-ott-11-5789] Therefore, it is of great importance to explore the molecular mechanisms underlying HBV-related HCC.

Previous studies demonstrated that HBV infection could lead to hypermethylation, and aberrant DNA methylation has been proved to be an early event in hepatocarcinogenesis.[@b30-ott-11-5789]--[@b32-ott-11-5789] Consequently, the analysis of DNA methylation could be an effective method for assessing reliable and powerful biomarkers for HBV-related HCC, which will greatly improve the diagnosis and treatment of it.

The GSTP1 is a gene encoding an enzyme with detoxifiation and protein-binding functions. In addition to the overexpression of GSTP1 observed in many neoplasms, GSTP1 genetic polymorphisms and abnormal CpG island methylation have also been thought to function in susceptibility to several cancers, including breast, lung, and liver cancers.[@b33-ott-11-5789]--[@b36-ott-11-5789] According to the previous studies, GSTP1 promoter methylation may be involved in the occurrence and development of HBV-related HCC.[@b15-ott-11-5789],[@b16-ott-11-5789],[@b18-ott-11-5789],[@b19-ott-11-5789] However, there are contradictory results concerning the role of GSTP1 promoter methylation in the progression of HBV-related HCC as well.[@b17-ott-11-5789],[@b20-ott-11-5789] In view of the conflicting evidence on this issue, we performed this meta-analysis to evaluate the exact relationship between GSTP1 promoter methylation and increased risk of HBV-related HCC. Consequently, our results confirmed that the methylation rates of GSTP1 gene in cancer tissues were considerably higher than those of normal controls (OR =6.05, 95% CI =1.20--30.52) as well as cirrhosis tissues (OR =5.21, 95% CI =2.19--12.41), suggesting the importance of GSTP1 promoter region methylation in the development of HBV-related HCC.

In addition, P16 is another important TSG for the suppression of tumor growth.[@b37-ott-11-5789],[@b38-ott-11-5789] P16 gene promoter region methylation represents the most common mechanism of P16 inactivation in HBV-induced human HCC.[@b39-ott-11-5789] As several studies demonstrated, the methylation of P16 may participate in the development of HBV-related HCC.[@b18-ott-11-5789],[@b19-ott-11-5789],[@b21-ott-11-5789],[@b22-ott-11-5789] However, the negative results indicated that the exact relationship of P16 gene promoter region methylation with HBV-related HCC susceptibility was still inconclusive.[@b17-ott-11-5789],[@b20-ott-11-5789] In the present study, an apparently increased risk of HBV-related HCC was found in tumor tissue in comparison with paracancerous tissue (OR =7.18, 95% CI =2.31--22.33), normal liver tissue (OR =24.89, 95% CI =3.38--183.03), and cirrhosis (OR =5.92, 95% CI =1.78--19.68), conforming that P16 promoter methylation is a risk factor for HBV-related HCC.

In this meta-analysis, the publication bias was examined in the eligible studies using Begg's test and Egger's test, and the funnel plots showed that the data did not have a considerable discrepancy among studies. Furthermore, we conducted sensitivity analysis and consistent results were found, which revealed that no single study could affect the overall conclusion.

However, several potential limitations must be empha-sized in this study. First, the limited studies with small sample size may limit the power of statistics. Second, moderate heterogeneity across included studies existed in separate comparisons, which may have an influence on the interpretation of our results. Third, as the pathogenesis of HBV-related HCC has a significant difference in diverse countries and regions, HBV genotypes B and C are common in Asia while genotypes A and D are prevalent in Europe, but the ethnicity of the population in this meta-analysis was mainly Asian. Therefore, the results of this meta-analysis were mainly adapted to Asian population, and large-scale subjects with multi-ethnic populations are needed.

Conclusion
==========

This meta-analysis showed that GSTP1 and P16 promoter methylation might play an important role in HBV-related HCC initiation and progression, and GSTP1 and P16 methylation in promoter region could obviously increase the risk of HBV-related HCC in patients with cirrhosis, which might be promising biomarkers for the early clinical diagnosis of HBV-related HCC. However, in consideration of the limitations mentioned earlier, more large-scale and well-designed studies will provide more insights into the role of GSTP1 and P16 promoter methylation in the risk and pathogenesis of HBV-related HCC.
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![Forest plots of GSTP1 promoter region methylation and the risk of HBV-related HCC.\
**Notes:** (**A**) Neoplasm vs normal tissues; (**B**) neoplasm vs cirrhosis tissues. Each square represents an OR for each specific study, with square sizes proportional to the weight. Weights are from random-effects analysis.\
**Abbreviations:** GSTP1, glutathione-S-transferase Pi 1; HBV, hepatitis B virus; HCC, hepatocellular carcinoma.](ott-11-5789Fig2){#f2-ott-11-5789}

![Forest plots of P16 promoter region methylation and the risk of HBV-related HCC.\
**Notes:** (**A**) Neoplasm vs adjacent tissues; (**B**) neoplasm vs normal tissues; (**C**) neoplasm vs cirrhosis tissues; (**D**) neoplasm vs CHB tissues. Each square represents an OR for each specific study, with square sizes proportional to the weight. Weights are from random-effects analysis.\
**Abbreviations:** CHB, chronic hepatitis B; HBV, hepatitis B virus; HCC, hepatocellular carcinoma.](ott-11-5789Fig3){#f3-ott-11-5789}

![Begg's funnel plot analysis for publication bias between GSTP1 methylation and HBV-related HCC susceptibility.\
**Notes:** (**A**) Neoplasm vs normal tissues; (**B**) neoplasm vs cirrhosis tissues.\
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![Begg's funnel plot analysis for publication bias between P16 methylation and HBV-related HCC susceptibility.\
**Notes:** (**A**) Neoplasm vs adjacent tissues; (**B**) neoplasm vs normal tissues; (**C**) neoplasm vs cirrhosis tissues; (**D**) neoplasm vs CHB tissues.\
**Abbreviations:** CHB, chronic hepatitis B; HBV, hepatitis B virus; HCC, hepatocellular carcinoma.](ott-11-5789Fig5){#f5-ott-11-5789}

###### 

Clinicopathological features of eligible studies

  Gene methylation                    References                     Year                  Country   Ethnicity        Method   Neoplasm   Adjacent   Normal   Cirrhosis   CHB                       
  ----------------------------------- ------------------------------ --------------------- --------- ---------------- -------- ---------- ---------- -------- ----------- ----- ---- ---- ---- ---- ----
  GSTP1                               Su et al[@b15-ott-11-5789]     2007                  China     Asian            MSP      17         13         8        22          --    --   --   --   --   --
  Chang et al[@b16-ott-11-5789]       2008                           China                 Asian     MSP              10       3          --         --       --          --    6    11             
  Feng et al[@b17-ott-11-5789]        2010                           China                 Mixed     MethyLight       8        4          --         --       13          12    --   --   --   --   
  Lambert et al[@b18-ott-11-5789]     2011                           France and Thailand   Mixed     Pyrosequencing   9        23         --         --       6           34    3    22   --   --   
  Qu et al[@b19-ott-11-5789]          2015                           China                 Asian     MSP              16       12         --         --       0           20    --   --   --   --   
  Dong et al[@b20-ott-11-5789]        2017                           China                 Asian     MethyLight       17       81         --         --       0           80    2    73   0    90   
  P16                                 Shim et al[@b21-ott-11-5789]   2003                  Korea     Asian            MSP      15         3          --       --          --    --   15   9    --   --
  Narimatsu et al[@b22-ott-11-5789]   2004                           Japan                 Asian     MSP              5        4          --         --       --          --    6    8    3    18   
  Zhang et al[@b23-ott-11-5789]       2006                           China                 Asian     MSP              29       3          4          28       --          --    15   26   3    51   
  Su et al[@b15-ott-11-5789]          2007                           China                 Asian     MSP              14       16         5          25       --          --    --   --   --   --   
  Zhu et al[@b24-ott-11-5789]         2007                           China                 Asian     MSP              11       12         4          19       --          --    --   --   9    16   
  Chang et al[@b16-ott-11-5789]       2008                           China                 Asian     MSP              10       3          --         --       --          --    9    8    --   --   
  Zhu et al[@b25-ott-11-5789]         2010                           China                 Asian     MSP              40       48         17         71       --          --    --   --   --   --   
  Um et al[@b26-ott-11-5789]          2011                           Korea                 Asian     MethyLight       22       24         --         --       0           2     0    45   --   --   
  Qu et al[@b19-ott-11-5789]          2015                           China                 Asian     MSP              18       10         --         --       0           20    --   --   --   --   

**Abbreviations:** M, methylation; U, unmethylation; MSP, methylation-specific polymerase chain reaction; CHB, chronic hepatitis B.

###### 

Meta-analysis of the associations of GSTP1 and P16 gene methylation with HBV-related HCC pathogenesis

  Clinical features                           Studies (n)   Model                  OR (95% CI)            *P*-value   Heterogeneity test   Publication bias          
  ------------------------------------------- ------------- ---------------------- ---------------------- ----------- -------------------- ------------------ ------ ------
  GSTP1 methylation (neoplasm vs normal)      4             Random-effects model   6.05 (1.20--30.52)     0.03        66.4                 0.03               0.09   0.04
  GSTP1 methylation (neoplasm vs cirrhosis)   3             Fixed-effects model    5.21 (2.19--12.41)     0.00        0.00                 0.62               1.00   0.58
  P16 methylation (neoplasm vs adjacent)      4             Random-effects model   7.18 (2.31--22.33)     0.00        74.2                 0.01               0.09   0.30
  P16 methylation (neoplasm vs normal)        2             Fixed-effects model    24.89 (3.38--183.03)   0.00        40.0                 0.20               1.00   --
  P16 methylation (neoplasm vs cirrhosis)     5             Random-effects model   5.92 (1.78--19.68)     0.00        60.1                 0.04               1.00   0.58
  P16 methylation (neoplasm vs CHB)           3             Random-effects model   12.12 (0.75--196.50)   0.08        90.0                 0.00               1.00   0.47

**Abbreviations:** HBV, hepatitis B virus; HCC, hepatocellular carcinoma; CHB, chronic hepatitis B.
